Our website uses essential cookies and, with your consent, additional cookies to measure performance and improve our services. Cookie Policy.
You can change your choice at any time.
Tag
In the randomized phase II PASS‑01 trial of first‑line metastatic pancreatic ductal adenocarcinoma (PDAC), progression‑free survival was similar between modified FOLFIRINOX and gemcitabine/nab‑paclitaxel, but overall survival and safety tre
The PREOPANC-2 trial compared neoadjuvant FOLFIRINOX and gemcitabine-based chemoradiotherapy in resectable and borderline resectable pancreatic cancer, finding no significant overall survival difference between the two regimens.
The CONKO-007 trial reveals that adding chemoradiotherapy after induction chemotherapy increases margin-negative (R0) resections in surgically treated unresectable pancreatic cancer but does not improve overall survival.
A large Japanese phase II/III trial shows nab-paclitaxel plus gemcitabine confers longer overall survival and better tolerability compared to mFOLFIRINOX and S-IROX in metastatic pancreatic cancer.